Savara announces patient journey map for people living with autoimmune pulmonary alveolar proteinosis (apap) accepted for poster presentation at the chest 2024 annual meeting

Langhorne, pa.--(business wire)--savara inc. (nasdaq: svra) (the company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the acceptance of an abstract for poster presentation at the chest 2024 annual meeting, taking place october 6-9 in boston. the company is also sponsoring an industry symposium at the meeting. details are as follows: accepted abstract title: “a patient journey map for people living with autoimmune pulmonary alveolar proteinosis (ap.
SVRA Ratings Summary
SVRA Quant Ranking